Patents by Inventor Helle Fabricius Woeldike

Helle Fabricius Woeldike has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • N-terminal modified FGF21 compounds
    Patent number: 9655974
    Abstract: Analogs of FGF21 carrying a modifying, substituted ethylene or benzyl group can be used for treatment or prevention of diabetes, dyslipidemia, obesity, cardiovascular diseases, metabolic syndrome, and/or Non Alcoholic Fatty Liver Disease (NAFLD).
    Type: Grant
    Filed: July 18, 2011
    Date of Patent: May 23, 2017
    Assignee: Novo Nordisk A/S
    Inventors: Tina Moeller Tagmose, Patrick William Garibay, Xujia Zhang, Henning Thoegersen, Peter Kresten Nielsen, Kristian Sass Bak-Jensen, Helle Fabricius Woeldike
  • BL21 strain lacking a functional group II capsular gene cluster
    Patent number: 8535909
    Abstract: The present invention relates to a novel non-pathogenic Escherichia coli (E. coli) B BL21 strain comprising a deletion of group II capsular gene cluster, and the use thereof for the production of peptides.
    Type: Grant
    Filed: November 10, 2009
    Date of Patent: September 17, 2013
    Assignee: Novo Nordisk A/S
    Inventors: Helle Fabricius Wöldike, Jianhui Deng, Xin Zhao, Yun Liu, Jing Su
  • N-TERMINAL MODIFIED FGF21 COMPOUNDS
    Publication number: 20130190232
    Abstract: Analogues of FGF21 carrying a modifying, substituted ethylene or benzyl group can be used for treatment or prevention of diabetes, dyslipidemia, obesity, cardiovascular diseases, metabolic syndrome, and/or Non Alcoholic Fatty Liver Disease (NAFLD).
    Type: Application
    Filed: July 18, 2011
    Publication date: July 25, 2013
    Applicant: NOVO NORDISK A/S
    Inventors: Tina Moeller Tagmose, Patrick William Garibay, Xujia Zhang, Henning Thoegersen, Peter Kresten Nielsen, Birgitte Andersen, Jishu Wang, Kristian Sass Bak-Jensen, Helle Fabricius Woeldike
  • E. COLI BL21 STRAIN LACKING A FUNCTIONAL GROUP II CAPSULAR GENE CLUSTER
    Publication number: 20110236929
    Abstract: The present invention relates to a novel non-pathogenic Escherichia coli (E. coli) B BL21 strain comprising a deletion of group II capsular gene cluster, and the use thereof for the production of peptides.
    Type: Application
    Filed: November 10, 2009
    Publication date: September 29, 2011
    Applicant: Novo Nordisk A/S
    Inventors: Helle Fabricius Wöldike, Jianhui Deng, Xin Zhao, Yun Liu, Jing Su
  • Expression of proteins in
    Patent number: 7858747
    Abstract: Plasmid comprising a DNA tag encoding a peptide tag of the sequence MX1(X2X3)n wherein X1 represents K, R or H; X2 represents A, G, H, M, S or T; X3 represents K, R, H, A, Q or V; n represents an integer of 1 or larger; and wherein said DNA is operably-linked to a promoter sequence are provided.
    Type: Grant
    Filed: August 30, 2006
    Date of Patent: December 28, 2010
    Assignee: Novo Nordisk A/S
    Inventors: Helle Fabricius Wöldike, Christine Bruun Schiødt
  • Process for the production of protein products in aspergillus
    Patent number: 7517668
    Abstract: A process for expression of a protein product in Aspergillus oryzae is disclosed. The process comprises transforming Aspergillus oryzae with a vector system comprising DNA-sequences encoding functions facilitating gene expression, a suitable marker for selection of transformants, and a DNA-sequence encoding the desired protein product. The process enables industrial production of many different polypeptides and proteins in A. oryzae. Examples of such products are chymosin or prochymosin other rennets, proteases, lipases and amylases. Also disclosed is an effective promoter for expression of a protein in Aspergillus. A preferred promoter is the TAKA-amylase promoter or functional parts thereof. There is also provided a process for the production of a recombinant Humicola lipase. The recombinant Humicola lipase from A. oryzae differs from the native lipase in having a greater glycosylation and in exhibiting an improved thermostability.
    Type: Grant
    Filed: May 5, 1995
    Date of Patent: April 14, 2009
    Assignee: Novozymes A/S
    Inventors: Esper Boel, Tove Christensen, Helle Fabricius Wöldike
  • Process for producing extracellular proteins in bacteria
    Patent number: 6171823
    Abstract: The invention relates to a method of producing an extracellular protein in a bacterium provided with an inner and an outer cell membrane, the method comprising: (a) providing a recombinant vector including a DNA construct comprising a DNA sequence encoding the prepropeptide or part of the prepropeptide of a bacterial extracellular protease selected from the group consisting of Achromobacter lyticus protease I, Bacillus metalloproteases and Bacillus serine proteases preceding and operably connected to a DNA sequence encoding a desired protein, (b) transforming cells of a microorganism provided with an inner and outer cell membrane with the recombinant vector of step (a), (c) culturing the transformed cells of step (b) under conditions permitting expression of said DNA insert and leakage of the bacterial extracellular protease propeptide fused to the desired protein into the culture medium, and (d) recovering the resulting protein from the medium.
    Type: Grant
    Filed: June 2, 1997
    Date of Patent: January 9, 2001
    Assignee: Novo Nordisk A/S
    Inventors: Helle Fabricius Wöldike, Sven Hastrup